u/IJesusChrist · 288d ago2 prior · 100% at 3mo
NMRA is next!
GLUE has positioned itself in NLRP3 with a different upstream target strategy and stands to benefit from LLY's acquisition of VTYX. As part of the broader pharma ecosystem watching this deal, GLUE should see upside.
At post $16.01Now $11.22-29.9% since postedas of Oct 21, 4:45 PM ET
1d+45.4%
3d+51.7%
1w+49.8%
1m+18.1%
3m+5.7%
6m+51.2%
1y—